Lobbying Information
Subject Matters
- Aboriginal Affairs
- Agriculture
- Biologics
- biotechnology
- Biotech policy
- Constitutional Issues
- Consumer Issues
- Data Protection Regulations
- Defence
- Economy
- Education
- Employment and Training
- Energy
- Environment
- Financial Institutions
- Financing for Emerging Biotech Companies
- Fisheries
- Forestry
- Government Procurement
- Health
- Immigration
- Industry
- Infrastructure
- Intellectual Property
- Internal Trade
- International Relations
- International Trade
- Justice and Law Enforcement
- Labour
- Pandemic Planning
- Regional Development
- Right of Appeal
- Science and Technology
- SEBs
- Small Business
- Sports
- Subsequent Entry Biologics
- Taxation and Finance
- Transportation
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
- Patent Act as it relates to further changes affecting patent term restoration
- User Fees Act with respect to cost recovery
Legislative Proposal, Bill or Resolution, Policies or Program
- Food and Drugs Act as it relates to modernization
Policies or Program
- Biologics and Genetic Therapies Directorate as it relates to policies affecting the review and approval of submissions
- Guidance for Industry: Issuance of Health Professional Communications and Public Communications by Market Authorization Holders and Draft Guidance Document: Triggers for Issuance of Risk Communication Documents for
Marketed Health Products for Human Use with respect to communications from manufacturers, health professionals and consumers, to the public via Health Canada and manufacturers, and Product Monographs
- Health Canada International Memorandum of Understanding with respect to exchanging data and safety protocols
- Health Canada Post Notice of Compliance Change Guidance: Quality with respect to the categorization of a change and the recommended supporting data for any changes to the Quality information associated with a new drug
- Implementation of the National Pharmaceutical Strategy as it affects the industry
- Pandemic Planning as it relates to the Task Group on Antiviral Prophylaxis recommendations
- Patent Act as it relates to changes to Canada's Access to Medicines Regime
- Patented Medicine Prices Review Board in respect of proposed Pricing Guidelines
- Progressive Licensing Framework with respect to its development and government consultations
- Science and Technology Strategy as it relates to new policies for the pharmaceutical industry
- Therapeutic Products Directorate's work as it relates the Guidance for Industry: Management of Drug Submissions with respect to the review and approval of submissions
Policies or Program, Regulation
- Creation of pathways for Subsequent Entry Biologics (SEBs) pertaining to Draft Guidance for Sponsors: Information and Submission Requirements for SEBs, regulations and intellectual property policies
Regulation
- Amendments to the Food and Drugs Act Regulations as it relates to further changes to data protection
- Data Protection Regulations with respect to its implementation and application to the Food and Drugs Act
- Patent Act as it relates to Patented Medicines (Notice of Compliance) Regulations and possible changes to modernize and Right of Appeal
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Aboriginal Affairs and Northern Development Canada
-
Agriculture and Agri-Food Canada (AAFC)
-
Atlantic Canada Opportunities Agency (ACOA)
-
Canadian International Development Agency (CIDA)
-
Canadian International Trade Tribunal (CITT)
-
Canadian Space Agency (CSA)
-
Canadian Transportation Agency (CTA)
-
Citizenship and Immigration Canada
-
Competition Tribunal (CT)
-
Correctional Service of Canada (CSC)
-
Environment Canada
-
Federal Office of Regional Development – Quebec (FORD[Q])
-
Finance Canada (FIN)
-
Foreign Affairs and International Trade Canada (DFAITC)
-
Health Canada (HC)
-
Human Resources Development Canada (HRDC)
-
Industry Canada
-
Justice Canada (JC)
-
Members of the House of Commons
-
National Defence (DND)
-
National Research Council (NRC)
-
Natural Resources Canada (NRCan)
-
Natural Sciences and Engineering Research Council (NSERC)
-
Office of the Auditor General
-
Office of the Information and Privacy Commissioner (OIPC)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Health Agency of Canada (PHAC)
-
Public Safety and Emergency Preparedness Canada (PSEPC)
-
Public Service Commission of Canada (PSC)
-
Public Works and Government Services Canada
-
Revenue Canada (RC)
-
Royal Canadian Mounted Police (RCMP)
-
Senate of Canada
-
Service Canada (ServCan)
-
Solicitor General Canada (SGC)
-
Statistics Canada (StatCan)
-
Transport Canada (TC)
-
Treasury Board Of Canada Secretariat (TBS)
-
Veterans Affairs Canada (VAC)
-
Western Economic Diversification Canada (WD)
Government institutions added through a monthly communication report
- Canadian Institutes of Health Research (CIHR)
In-house Corporation Details
Description of activities
Hoffmann-La Roche Limited deals with the healthcare system in the prevention, screening, diagnosis, treatment and management of acute and long-term disease and supports leading research and development - including clinical research, clinical trials and genetic research.
Responsible officer name and position during the period of this registration
RONNIE MILLER,
PRESIDENT AND CHIEF EXECUTIVE OFFICER
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
2455 Meadowpine Blvd.
Mississauga, ON L5N 6L7
Canada
Telephone number:
905-542-5555
Fax number:
905-542-7130
Parent Company Information
- F. Hoffmann-La Roche AG
-
Grenzacherstrasse 124
4070 Basle
Switzerland
Subsidiary Beneficiary Information
Hoffmann-La Roche Limited does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Ciro Caravaggio,
Vice President, Oncology, Hematology & Rheumatology Business Units |
No public offices held
- James Hall,
Vice President, Urgent Care, Transplant, Virology & AVA Business Units |
No public offices held
- RONNIE MILLER,
PRESIDENT AND CHIEF EXECUTIVE OFFICER |
No public offices held
- James Willoughby,
Vice President, General Counsel & Corporate Secretary |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Michèle Beaubien,
Executive Director, Government and Corporate Affairs |
No public offices held
- Lorenzo Biondi,
Vice President, Medical & Regulatory Affairs |
No public offices held
- Linnea Doyle,
Director of Market Access |
No public offices held
- Linda Jack,
Director Regulatory Affairs |
No public offices held
- Brigitte Nolet,
Director, Government Relations and Health Policy, Specialty and Urgent Care |
Public offices held
- Elizabeth Peace,
Manager, Government Relations and Health Policy |
Public offices held
- Sammy Su,
Product Manager |
No public offices held
- Ilona Torontali,
Vice President, Public Affairs |
No public offices held
